Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Once-weekly TransCon CNP has demonstrated its potential to transform the treatment of achondroplasia, positioning it as a potential long-term foundation of care

  80% confidence

• It is encouraging to see meaningful improvements in arm span and body proportionality alongside changes in linear height, as these endpoints provide important context beyond height alone

  80% confidence

• Combination therapy with TransCon CNP and TransCon hGH may set new treatment standards with clinically meaningful improvements in growth, body proportionality, and arm span with a safety and tolerability profile essential for long-term use in children

  80% confidence

• Rational dual-agent regimens such as TransCon CNP and TransCon hGH combination may become a new standard of care in achondroplasia and other growth disorders

  80% confidence

• The combination data underscore the potential of TransCon CNP to become the backbone therapy for addressing the underlying biology of achondroplasia, with TransCon hGH providing complementary benefit

  80% confidence

• The COACH Trial has demonstrated unmatched improvements in growth and benefits beyond linear growth without compromising safety or tolerability compared to historical data

  80% confidence

• Data like COACH trial results may help expand the range of options individuals and families consider as they weigh what matters most to them in achondroplasia treatment

  80% confidence